Oral MucositisPhase 1NCT00701688
Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 1 study testing Palifermin in people with Oral Mucositis and Hematopoietic Stem Cell Transplantation, run by St. Jude Children's Research Hospital at 1 site in United States.
Trial summary
Mucositis is a well-known complication of both autologous and allogeneic hematopoietic stem cell transplantation (HSCT). Many who suffer this disorder require total parental nutrition and intravenous narcotics for pain control. Read more about this study
- Who is it for?
- Ages 2 to 18 years
- Conditions the study is for
- Oral Mucositis, Hematopoietic Stem Cell Transplantation
- What is being tested?
- Palifermin
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 19 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2007to Feb 2012
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Age greater than or equal to 2 years and less than 18 years of age.
- Diagnosis of a hematologic malignancy.
- Has not received a prior autologous or allogeneic HSCT.
- Is scheduled to receive either a matched family member or MUD bone marrow stem cell graft at St. Jude Children's Research Hospital. A matched family member donor is defined as a sibling matched at 5 or 6 HLA loci or another related donor matched at 6 HLA loci.
- Is scheduled to receive a myeloablative preparative regimen (cyclophosphamide/TBI based) prior to the infusion of the allogeneic graft.
- Cardiac shortening fraction greater than or equal to 25%.
Show all 17Show fewer
- Serum creatinine is less than twice the upper limit of normal for age.
- Bilirubin less than 3.0 mg/dl.
- Aspartate transaminase (AST) less than 500 IU/ml.
- Alanine transaminase (ALT) less than 500 IU/ml.
- Amylase less than 1.5 times the upper limits of normal for age.
- Lipase less than 1.5 times the upper limits of normal for age.
- Forced vital capacity (FVC) greater than or equal to 40% of predicted value or pulse oximetry greater than or equal to 92% on room air.
- No known hypersensitivity to E coli-derived proteins or palifermin.
- No active or recent (within 30 days prior to enrollment) gastrointestinal bleeding.
- No active or recent (within 30 days prior to enrollment) oral ulcerations.
- No active fungal infection, bacteremia or viremia within two weeks prior to enrollment.
Who cannot join
- Female - pregnant (negative serum or urine pregnancy test within 14 days prior to enrollment).
- Female - lactating.
Trial locations and contacts
1 site in 1 country.
United States1 site
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105
About this study
Official title: Phase I Study Of The Use Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Mucositis is a well-known complication of both autologous and allogeneic hematopoietic stem cell transplantation (HSCT). Many who suffer this disorder require total parental nutrition and intravenous narcotics for pain control. Palifermin (Kepivance[TM]) is a human keratinocyte growth factor that is produced by recombinant DNA technology in E. coli. Palifermin is a FDA-approved, commercially available pharmacologic agent that is manufactured by Amgen. As keratinocyte growth factor receptors have been found within the epithelium of gastric mucosa, the use of palifermin has been proven to decrease the frequency and duration of severe mucositis in adult studies. Whereas the appropriate dosing regimen has been determined for adults at 60mcg/kg/day, the dosing of palifermin has not been established in the pediatric setting. This initial pediatric study of palifermin will determine the maximum tolerated dose, evaluating the use of this agent at three dose levels, below, at, and above the recommended adult dose. Non-hematologic, life-threatening NCI grade IV or grade V toxicities definitely related to the administration of palifermin from the first infusion until day +6 after HSCT (post palifermin administration day +3) will comprise the safety endpoints of the study.
The study is designed to evaluate palifermin at 3 dose levels. The study population will be recipients of either a matched family member donor or matched unrelated donor HSCT. The pharmacokinetics of palifermin at each dose level will be described to help determine the appropriate dose for future studies, which will evaluate efficacy
Read the detailed description
Secondary objectives of this study include exploring the pharmacoeconomics of palifermin in this particular patient population through an assessment of inpatient days, intravenous nutrition, and analgesia requirements within 100 days post-transplantation. We will also explore the research participants' rates of immune reconstitution, specifically T and B-lymphocytes and NK cells, within the first year of HSCT.
- Being tested
- Palifermin
- Keywords
- Mucositis, Oral, Hematopoietic Stem Cell Transplantation, Allogeneic Transplantation, Pharmacokinetics, Maximum Tolerated Dose
- Medical subject headings
- Stomatitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PaliferminDrug
Also called Kepivance®
Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous
| Study group | Role | What they receive |
|---|---|---|
| Dose Level 1 | Experimental | Palifermin 40 mcg/kg/day intravenous Receives: Drug: Palifermin |
| Dose Level 2 | Experimental | Palifermin 60 mcg/kg/day intravenous Receives: Drug: Palifermin |
| Dose Level 3 | Experimental | Palifermin 90 mcg/kg/day intravenous Receives: Drug: Palifermin |
What is being measured
The primary outcome is the main question the study is designed to answer.
To determine the maximum tolerated dose and describe the toxicity profile of palifermin in pediatric research participants with hematologic malignancies undergoing first HSCT.
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jun 2008 (estimated)
- Study startSep 2007
- Primary completionSep 2011
- Study completionFeb 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oral MucositisStudies of the same condition, open and under way.
- More trials run by St. Jude Children's Research HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 19 participants (actual)
Sponsor and investigators
- Lead sponsor
- St. Jude Children's Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ashok Srinivasan, MD, Principal investigator, St. Jude Children's Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00701688
- Sponsor's protocol ID
- PALSCT
- Status last verified
- Mar 2012
- First submitted
- 17 Jun 2008
- Last updated
- 23 Mar 2012
- Results posted
- No
- Data monitoring committee
- No